Biologically Active Substance
Lilly says further head-to-head trial data back Zepbound over Novos Wegovy
Tirzepatide, Semaglutide, Weight Loss, Obesity Treatment, SURMOUNT-5 Trial, Comparative Efficacy
Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI
Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color
Teva plots thousands of job cuts as restructuring drive enters ‘acceleration’ phase
Workforce reduction (8%), $700 million cost savings, Strategic overhaul, Generics to biopharmaceuticals pivot, Operational streamlining, R&D investment
Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides
MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1
CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%
Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes
PTC crashes as win for Novartis-partnered Huntington’s drug fails to convince investors
factor IX, PTC518, Accelerated, Approved, United States Food and Drug Administration
PTC’s Novartis-partnered Huntington’s drug disappoints in mid-stage data reveal
PTC518, factor IX, Huntington ‘s disease, Market
FDA lifts clinical hold on Atara’s Epstein-Barr T-cell programme
United States Food and Drug Administration, Study on Hold, Atara, Hoist device, Atara ‘s, EBVALLO
Novo eyes fourth-quarter FDA verdict for oral Wegovy filing
Obesity, Novo, United States Food and Drug Administration, Decision, Oral cavity, Wegovy, semaglutide, Overweight
Exclusive: Vertex drops AAV gene therapy research, tRNA therapy partnership
gene therapy, Dependovirus, Transfer RNA, Partnership, Industry, research, Safety